Royalty Pharma Plc (RPRX NASDAQ) stock market data APIs
$67.4435
-0.69(-1%)
as of October 30, 2026
Try our APIs with
free plan!
Royalty Pharma Plc Financial Data Overview
Price chart is built with
Anychart
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Prev. Close
67.4435
Open
66.7579
High
68.3144
Low
66.5961
52 wk Range
35.3416-67.705
Market Cap
38 819 M
P/E Ratio
35.734
Shares Outstanding
445 M
Revenue
2 536 M
Dividends (Yield)
0.0138
Beta
0.412
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Royalty Pharma Plc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Royalty Pharma Plc data using free add-ons & libraries
Get Royalty Pharma Plc Fundamental Data
Royalty Pharma Plc Fundamental data includes:
- Net Revenue: 2 536 M
- EBITDA: 1 557 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-04
- EPS/Forecast: 1.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Royalty Pharma Plc News
New
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
In its upcoming report, Royalty Pharma (RPRX) is predicted by Wall Street analysts to post quarterly earnings of $1.18 per share, reflecting an increase of 0.9% compared to the same period last year. ...
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Guardant Health (GH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook g...
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Royalty Pharma (RPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook ...
Funds Load Up On Marriott, Estee Lauder As Big Tech Earnings Loom
Funds played defense as they load up on Marriott, Estee Lauder and biotech and energy names in Tuesday's stock market. Continue Reading
Get Royalty Pharma Plc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.